Abstract
Intrinsic or acquired resistance to chemotherapy is a major clinical problem that has evoked the need to develop innovative approaches to predict and ultimately reverse drug resistance. A prolonged G2M arrest has been associated with apoptotic resistance to various microtubule-targeting agents (MTAs). In this study, we describe the functional significance of the mitotic spindle checkpoint proteins, BubR1 and Bub3, in maintaining a mitotic arrest after microtubule disruption by nocodazole and a novel series of MTAs, the pyrrolo-1,5-benzoxazepines (PBOXs), in human cancer cells. Cells expressing high levels of BubR1 and Bub3 (K562, MDA-MB-231, and HeLa) display a prolonged G2M arrest after exposure to MTAs. On the other hand, cells with low endogenous levels of mitotic spindle checkpoint proteins (SK-BR-3 and HL-60) transiently arrest in mitosis and undergo increased apoptosis. The phosphorylation of BubR1 correlated with PBOX-induced G2M arrest in four cell lines tested, indicating an active mitotic spindle checkpoint. Gene silencing of BubR1 by small interfering RNA interference reduced PBOX-induced G2M arrest without enhancing apoptotic efficacy. Further analysis demonstrated that PBOX-treated BubR1-depleted cells were both mononucleated and multinucleated with a polyploid DNA content, suggesting a requirement for BubR1 in cytokinesis. Taken together, these results suggest that BubR1 contributes to the mitotic checkpoint induced by the PBOXs.
Footnotes
-
This study was supported by Science Foundation Ireland.
-
ABBREVIATIONS: MTA, microtubule-targeting agent; PBOX, pyrrolo-1,5-benzoxazepine; PBOX-6, 7-[(dimethylcarbamoyl) oxy]-6-(2-naphthyl)pyrrolo-[2,1-d][1,5]benzoxazepine; PBOX-15, 4-acetoxy-5-(-1-(naphthyl)naphtho[2,3-b]pyrrolo[2,1-d] [1,4]oxazepine; PARP, poly(ADP-ribose) polymerase; APC/C, anaphase-promoting complex/cyclosome; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; DMSO, dimethyl sulfoxide; mAb, monoclonal antibody; siRNA, small interfering RNA; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; TBS-T, Tris-buffered saline, pH 7.6/0.05% Tween 20; PI, propidium iodide; PBST, PBS and 0.1% Triton X-100; ZM447439, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide.
-
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received June 20, 2007.
- Accepted November 8, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|